logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9408863 B1

PDFFull Text
Date of Patent:
Aug. 09, 2016

Filed:

Jul. 10, 2012

5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases

Applicants:

Vishal A. Verma, Jersey City, NJ (US);

Ashok Arasappan, Bridgewater, NJ (US);

F. George Njoroge, Carmel, IN (US);

Kevin X. Chen, Edison, NJ (US);

Inventors:

Vishal A. Verma, Jersey City, NJ (US);

Ashok Arasappan, Bridgewater, NJ (US);

F. George Njoroge, Carmel, IN (US);

Kevin X. Chen, Edison, NJ (US);

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:

Jeffrey P. Bergman

Catherine D. Fitch

Primary Examiner:

Lawrence E Crane

Int. Cl.
CPC ...
A01N 43/04 (2006.01); A61K 31/70 (2006.01); C07H 19/20 (2006.01); C07H 19/10 (2006.01); C07H 19/04 (2006.01); C07H 19/048 (2006.01); A61K 31/7056 (2006.01); A01N 37/46 (2006.01); C07H 19/06 (2006.01); C07H 19/16 (2006.01); A61K 31/341 (2006.01); A61K 31/4196 (2006.01); A61K 31/7068 (2006.01); A61K 31/7072 (2006.01); A61K 31/7076 (2006.01); A61K 31/708 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/7056 (2013.01); A01N 37/46 (2013.01); A61K 31/341 (2013.01); A61K 31/4196 (2013.01); A61K 31/708 (2013.01); A61K 31/7068 (2013.01); A61K 31/7072 (2013.01); A61K 31/7076 (2013.01); A61K 45/06 (2013.01); C07H 19/06 (2013.01); C07H 19/10 (2013.01); C07H 19/16 (2013.01); C07H 19/20 (2013.01);
Abstract

The present invention relates to 5'-Substituted Nucleoside Analogs of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, Z, R, R, Rand Rare as defined herein. The present invention also relates to compositions comprising at least one 5′-Substituted Nucleoside Analog, and methods of using the 5′-Substituted Nucleoside Analogs for treating or preventing HCV infection in a patient.

Find Patent Forward Citations

Loading…